Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home

Asthma Clinical Trial

— OCTAGEN  

Official title:

Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01783132
• Other study ID #: 1852011
• Status: Terminated
• Phase: N/A
• Start date: December 1, 2012
• Est. completion date: April 28, 2014

Study information

• Verified date: September 2019
• Source: Orion Corporation, Orion Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the clinical outcome (effectiveness) of single inhaled corticosteroid (ICS) controller treatment guided by exhaled NO measurement made at home with usual care asthma management with regard to asthma control (primary outcome), asthma-related quality of life, lung function, airway inflammation, medication use, and asthma events.

To understand changes in patient behaviour triggered by daily FENO measurement at home, for example treatment adherence and voluntary allergen exposure.

Description:

The design is a pragmatic randomized controlled, open-label, parallel group study Screening visit 1 and visit 2 is separated with a 2-4 week run-in period. At screening visit, Informed Consent is signed and atopic asthma confirmed, spirometry is performed and questionnaires responded to. At visit 2 venous blood samples are taken and serum stored at -20 °C for later transport to Uppsala Biobank, Exhaled NO is measured at both visit using NIOX MINO (blinded in control group).

• The active group if on combination inhaler, will switch to Giona Easyhaler (same budesonide equivalent as before study entry) and Oxis (same formoterol equivalent as before study entry). These patients will receive a NIOX MINO and will be taught about the adjustment of ICS treatment according to daily exhaled NO measurement at home and a personalized treatment algorithm.

• The control group will stay on previous controller treatment (only changed if indicated by symptoms at visit) according to usual care.

• Both groups will switch short-acting beta-2-agonist to Buventol Easyhaler.

• Both groups will report symptoms (ACQ) monthly and in connection to asthma events via an ePRO system (ViedocMe, PCG). Active group will report NO values on a weekly basis via the same system.

There will be a follow-up clinic visit 3 at 6 months with exhaled NO measurement (blinded in control group) and limited set of questionnaires. A second follow-up visit 4 at 12 months with exhaled NO, spirometry, full set of questionnaires and blood sample will be made.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 142
• Est. completion date: April 28, 2014
• Est. primary completion date: April 1, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Age =18, =64 years

• Physician-diagnosis of asthma

• Regular inhaled budesonide (Giona Easyhaler, Pulmicort Turbuhaler, Novopulmon Novolizer or Symbicort Turbuhaler) treatment since at least 6 months

• Verified allergy to at least one airborne perennial allergen after objective testing (ImmunoCAP Rapid Asthma/Rhinitis Adult)

• ACQ >1.0

• Can read and understand the Swedish language

• Written informed consent signed

Exclusion Criteria:

• Regular tobacco use within past 6 months

• =10 pack-years smoking history

• Keeping a furred pet at home

• Treatment with Singulair

• >4 prednisolone courses last 12 months

• Ongoing pregnancy or lactation

• Participation in another clinical trial

Related Conditions & MeSH terms

• Asthma

Intervention

Device:
• NIOX MINO
Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.

Locations

Country	Name	City	State
Sweden	Lungkliniken, Universitetssjukhuset i Uppsala	Uppsala

Sponsors (2)

Lead Sponsor	Collaborator
Orion Corporation, Orion Pharma	Aerocrine AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asthma symptoms in correlation to grade of inflammation in airways	To determine if ICS treatment guided by daily FENO measurement with a device "NIOX MINO" at home will improve asthma symptom control compared to usual care asthma management	Up to 1 year